July 26, 2022

Re: Surgical Outcomes System | Important Change

Dear SOS User and Stakeholder,

We are reaching out to you to inform you about the future of the Arthrex Surgical Outcomes System (SOS). SOS has been a successful program within the last twelve years, although with evolving regulatory requirements for clinical research and much deliberation, **Arthrex has determined to deactivate SOS by August 1, 2023** to optimize future clinical research efforts.

No action is required, additional information is located in the FAQ document.

ACHIEVEMENTS

Since its founding, Arthrex has had an uncompromising dedication to quality assurance and patient outcomes and a single, unwavering commitment to *Helping Surgeons Treat Their Patients Better*®. Our commitment to scientific evidence has led us to pioneer the patient-reported outcome field. This resulted in an extraordinary success with SOS with over 40 peer-reviewed publications, established registries for key initiatives, and numerous clinical reports.

EVOLVING REQUIREMENTS

As the market, our customers' needs, and associated clinical research standards evolve, we are focusing our efforts on solutions that will satisfy the regulatory requirements to support our advanced technologies and techniques.

As a recent example, Shoulder Arthroplasty Research Committee (ShARC) registry with over 2,000 patients was successfully transferred to another software platform to meet modern requirements for clinical outcomes and imaging analysis. Additionally, for our EU regulatory-driven studies we have leveraged a third-party software platform to ensure compliance with stringent standards and customized modules.

CONSEQUENCE FOR SOS

As a result, and with much deliberation, Arthrex has determined to deactivate SOS by August 1, 2023. This will not impact our strategic plan for research but Arthrex understands that it may impact you and your patient workflow. Therefore, Arthrex is committed to ensuring a smooth transition from SOS and will support you in extracting your data until deactivation. We remain dedicated to research collaborations via our Arthrex Study Portal and welcome investigator-initiated research requests. The attached Data Export Guide is attached for your convenience. For any immediate questions, please reach out to SOS@arthrex.com.

Please note that Arthrex does not intend to notify SOS enrolled patients about the deactivation of the platform to allow for personalized communications to be distributed by each SOS subscriber individually. In closing, we thank everyone for their support of the first global orthopedic registry these last twelve years. We believe that the future will require strategic focus in clinical data collection and Arthrex is primed to lead this challenge. We look forward to working with you on this endeavor.

Respectfully,

Coen A. Wijdicks, PhD, MBA
Sr. Director | Global Research | Arthrex, Inc